Farmacologia y Toxicologia

The global pharmaceutical industry revenue is forecasted to reach an estimated $1,226.0 billion by 2019, with good growth over the next five years (2013-2019). The industry is expected to register growth led by aging population, changing lifestyles, hectic daily activities, unhealthy eating habits, increasing incidence of chronic diseases across the entire global population providing growth opportunities for the industry players.

The industry is engaged in discovery, development, manufacture, and marketing of prescription drugs. Industry products include ethical drugs and consumer healthcare but animal healthcare drugs are not included. The global pharmaceutical market faces major challenge from increasing investment and strict regulation. Changing lifestyles and the fast socio-demographic shift due to urbanization in both developed and growth markets globally are expected drive the demand. The ability to create new technology and innovative drugs is a key driver for success in this market. North America is projected to lead the pharmaceutical industry. Vaccine industry is expected to record the highest growth during the forecast period. ROW industry is expected to witness the highest growth during 2013-2019. Government initiatives in Brazil to encourage drugs industries by providing free pricing policies and special financial investment options will attract the industry players. APAC holds good growth potential for the future.

This study provides an overview of the global pharmaceutical industry by tracking 13 market segments of that industry in four geographic regions. Thus, a total of 52 segments of the global pharmaceutical industry are tracked. The report studies manufacturers of bone, respiratory, immunology and dermatology, cardiovascular, diabetes & obesity, urinary/kidney diseases, gastrointestinal, neurosciences, infectious diseases, ophthalmology, oncology, women’s health/ endocrine, vaccines, consumer health/OTC, and others providing a five-year (2007-2012) annual trend analysis that highlights market size, profit and cost structure for NA, Europe, APAC, and ROW. This comprehensive guide provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global pharmaceutical industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.

The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval.15 U.S generic drug sales reached an estimated $70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and 4th World Conference on Pharmaceutical Research and Drug Management monetary crisis. According to the Quintiles IMS Institute predicts that the pharmaceutical market by 2021 will reach nearly USD 1,485 billion, by an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. Global brand spending is forecast to increase to USD 815-832 billion in 2021. Global generic spending is expected to increase to USD 495-505 billion by 2021.

Major Pharma Associations around the Globe:

• International Pharmaceutical Federation (FIP)
• International Pharmaceutical Students' Federation (IPSF)
• European Association of Employed Community Pharmacists in Europe (EPhEU)
• Pharmaceutical Group of the European Union (PGEU)
• National Pharmacy Association
• Pharmaceutical Society of Northern Ireland
• Royal Pharmaceutical Society (RPS)

These data describe the outcome of the patient as defined in U.S reporting regulations. Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life threatening. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacy.

Market Analysis of Global Pharmaceutical Industries:

The worldwide $1.12 trillion market in 2022 will ascend at a quicker clasp during 2016-2020, at that point hinder a piece as significant patent lapse grab hold. It is normal that the worldwide market declined by 1.0% in 2015 yet will develop by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022 and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now. The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is anticipated to reach $41.4 billion of every 2012 and $79 billion of every 2017, a five-year compound yearly development rate (CAGR) of 13.8%. There is a need to hinder genuine unfriendly impacts brought about by the medications by improving medication focusing through examination in pharmacology.